Chronic Kidney Disease (CKD)
10% of the population is affected by CKD, which is a leading cause of mortality and morbidity around the world.
CKD patients are suffering from late diagnosis and a lack of medication targeting the causes of the pathology, while the current treatments are focused on the symptoms only.
Despite the significant efforts and budgets allocated to develop new therapies, drug development companies are facing a high rate of clinical trial failures, mainly due to non-efficient preclinical explorations. NEPHRIX Biosolutions mission is to facilitate the preclinical step of drug development by providing efficient in vitro and in vivo models that most accurately predict the clinical outcomes.
In Vitro tools issues:
- Low physiological relevance (2D cell cultures)
- Lack of reproducibility (organoides, organ-on-chip)
In Vivo tools issues:
- Absence of early disease stage prediction (only late biomarkers available)